

A Weekly FAX from the Center for Substance Abuse Research

University of Maryland, College Park

DEA Temporarily Classifies Synthetic Marijuana as a Schedule I Drug

Synthetic marijuana packaged as incense or potpourri has spurred more than 4,500 "fake pot" calls to U.S. poison centers since 2010, prompting the Drug Enforcement Administration to recently temporarily classify it as a Schedule I drug.

What is synthetic marijuana? Synthetic marijuana is a blend of herbs and plant material sprayed with one or more synthetic cannabinoids, synthesized chemical compounds that bind to the same cannabinoid receptors as THC. Synthetic cannabinoids were originally created in a lab as potential pharmaceutical agents.

What are other names for synthetic marijuana? The most recognizable brand names are Spice and K2. More than 100 other brand names of have been identified, including Blaze, Fire 'n' Ice, G-Force, Solar Flare, and Yucatan Fire.

Where is synthetic marijuana sold? Synthetic marijuana is packaged in small pouches or packets and sold as herbal incense or potpourri that is labeled "Not for Human Consumption." Until the recent DEA ban, it was legally sold in head shops, smoke shops, liquor stores, convenience stores, gas stations, and over the internet.

Who uses synthetic marijuana? Qualitative evidence suggests that the primary users are teenagers and young adults as well as cannabis users. According to the DEA, a major private toxicology laboratory reported that 30% to 35% of specimens submitted by juvenile probation departments were positive for synthetic marijuana.

What are the effects of synthetic marijuana use? Research as to the potency and side effects is new and limited. However, it appears that the psychoactive effects of synthetic marijuana are similar to marijuana, and there is some evidence that synthetic marijuana may even be more potent depending on the specific synthetic cannabinoid. Adverse effects include increased heart rate and blood pressure, extreme anxiety, agitation, disorientation, paranoia, hallucinations, vomiting, and tremors. There were 2,874 calls received by U.S. poison centers about synthetic marijuana products in 2010. As of April 20, 2011, 1,639 calls had been received in 2011.

Can you become dependent on synthetic marijuana? The limited research available to date indicates that synthetic marijuana may have the potential for dependence. There has been one documented case of dependency based on both DSM-IV and ICD-10 criteria, including tolerance and physical withdrawal symptoms. The European Monitoring Centre for Drugs and Drug Addiction suggests that "it seems tolerance to these synthetic cannabinoids may develop fairly fast, and arguably this might be associated with relatively high potential to cause dependence" (p. 12).

Can it be detected by drug tests? While synthetic marijuana will not be detected by standard drug tests that screen for marijuana, several national laboratories offer tests for synthetic cannabinoids.

What are the current laws regarding synthetic marijuana in the U.S.? As of May 4, 2011, 24 states have enacted legislation and 24 states have legislation pending banning one or more synthetic cannabinoids. In March 2011, the DEA temporarily classified five of the synthetic cannabinoids used in synthetic marijuana as Schedule I drugs, which is reserved for those substances with high potential for abuse, no accepted medical use for treatment in the U.S., and a lack of accepted safety use of the drug under medical supervision. This classification can last up to one year, with a 6-month extension, allowing the DEA and the U.S. Department of Health and Human Services time to determine whether these chemicals should be permanently controlled. Based on Europe's experience with regulating synthetic marijuana, it is possible that current laws will be circumvented by the production and use of new synthetic cannabinoids not covered by current legislation.

SOURCE: A complete list of sources is available by accessing the PDF version of this issue online at www.cesar.umd.edu.

•• 301-405-9770 (voice) •• 301-403-8342 (fax) •• CESAR@cesar.umd.edu •• www.cesar.umd.edu •• *CESAR FAX* may be copied without permission. Please cite CESAR as the source.

CESAR FAX Volume 20, Issue 17 (May 9, 2011) Source List

- "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids into Schedule I," *Federal Register* 76(40): 11075-11078, March 1, 2011.
- American Association of Poison Control Centers, "Fake Marijuana Spurs More Than 4,500 Calls to U.S. Poison Centers," *Press Release*, April 20, 2011. Available online at http://www.aapcc.org/dnn/Portals/0/prrel/revisedk2releaseapril20.pdf.
- Atwood, B.K., Huffman, J., Straiker, A., Mackie, K., "JWH018, a Common Constituent of 'Spice' Herbal Blends, Is a Potent and Efficacious Cannabinoid CB Receptor Agonist," *British Journal of Pharmacology*, 160(3):585-593, 2010.
- Dargan, P.I., Hudson, S., Ramsey, J., Wood, D.M. "The Impact of Changes in UK Classification of the Synthetic Cannabinoid Receptor Agonists in 'Spice'," *International Journal of Drug Policy*, April 7, 2011, doi:10.1016/j.drugo.2011.02.006.
- Dresen, S., Kneisel, S., Weinimann, W., Zimmermann, R., Aüwarter, V. "Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantitation of Synthetic Cannabinoids of the Aminoalkylindole Type and Methanandamide in Serum and Its Application to Forensic Samples," *Journal of Mass Spectrometry*, 46:163-171, 2010.
- Drug Enforcement Administration, "Chemicals Used in 'Spice' and 'K2' Type Products Now Under Federal Control and Regulation," *Press Release*, 3/1/2011. Available online at http://www.justice.gov/dea/pubs/pressrel/pr030111.html.
- Drug Enforcement Administration, Office of Diversion Control, National Forensic Laboratory Information System (NFLIS) Year 2009 Annual Report, 2010.
- Drug Enforcement Administration, Office of Diversion Control, National Forensic Laboratory Information System (NFLIS) Year 2008 Annual Report, 2009.
- European Monitoring Centre for Drugs and Drug Addiction, "Understanding the 'Spice' Phenomenon," *Thematic Papers*, 2009.
- European Monitoring Centre for Drugs and Drug Addiction, *Annual Report 2010: The State of the Drugs Problem in Europe*, 2010.
- Müller, H., Sperling, W., Köhrmann, M., Huttner, H., Kornhuber, J., Maler, J-M. "The Synthetic Cannabinoid Spice as a Trigger for an Acute Exacerbation of Cannabis Induced Recurrent Psychotic Episodes," *Schizophrenia Research*, 118(1-3): 309-310, 2010.
- National Conference of State Legislatures, *Legislation on Synthetic Cannabinoids as of May 4, 2011*, online at http://www.ncsl.org/?TabId=22431, accessed 5/6/2011.
- National Drug Court Institute, "Spice, K2, and the Problem of Synthetic Cannabinoids," Drug Court Practitioner Fact Sheet, 6(1), 2010.

- National Drug Intelligence Center, U.S. Department of Justice, "Use of Synthetic Cannabinoid Products by Teens and Young Adults Increasing," *Drug Alert Watch*, 2010.
- Redwood Toxicology Laboratory, "Redwood Toxicology Laboratory Announces Oral Fluid Test for Synthetic Cannabinoids: JWH-018, JWH-073 and JWH-250," *Press Release*, November 15, 2010.
- Redwood Toxicology Laboratory, "Redwood Toxicology Laboratory Announces Urine Test for Marijuana Mimics: Synthetic Cannabinoids JWH-018 and JWH-073 Metabolites," *Press Release*, July 12, 2010.
- Schneir, A.B., Cullen, J., Ly, B.T., "Spice' Girls: Synthetic Cannabinoid Intoxication," *The Journal of Emergency Medicine*, 40(3):296-299, 2011.
- U.S. Naval Criminal Investigative Service, Norfolk Field Office, *Introduction to Spice*, 2010.
- United States Drug Testing Laboratories, "USDTL Synthetic Cannabinoid Urine Test Stems from Increasing Illicit Use," *Press Release*, April 18, 2011.
- Vardakou, I., Pistos, C., Spiliopoulu, Ch. "Spice Drugs as a New Trend: Mode of Action, Identification and Legislation," *Toxicology Letters*, 197(3):157-16, 2010.
- Zimmerman, U. S., Winkelmann, M. P., Nees, J. A., Spanagel, R., Schulz, K., "Withdrawal phenomena and dependence syndrome after the consumption of 'spice gold'," *Deutsches Arzteblatt International*, 106(27):464-467, 2009.